|
Cancer
is the most dreaded and prevalent disease in current times without yet a
confident cure or even satisfactory management protocols in sight, in
spite of the enormous amounts time, money and energy spent on cancer
research in the past quarter century. This is one disease that attracted
the attention of a very large number of experts in every system of
medicine, physiology and genetics. An overview of various aspects of
cancer can be had from the review articles in the special issue of
Scientific American of September, 1996.
CRITERIA
FOR AN ANTI-NEOPLASTIC DRUG
An antineoplastic
(anticancer) drug should be:
a) cytotoxic: to inhibit
the cancer cell’s metabolism particularly synthesis of proteins and
nucleic acids, in order to prevent cell
growth, differentiation, vascularisation of the new growth,
etc.;
b) mitostatic: to disrupt
the process of cell division to prevent the uncontrolled number of cycles
of cell division and growth, to retard the proliferation of the cancerous
tissue;
c) nontoxic: the drug
should be nontoxic to the rest of the body of the patient; it should not
cause any side effects such as renal or
hepatic dysfunction, neurotoxicity, hypersensitivity, etc.; and
d) target oriented: it
should be site-selective targetting its action to the cancerous region
and not cause the same effects (or at least
not cause them to the same degree as on cancer)
on the other parts of the patient’s body.
In addition, the drug
should be effective in small and/or few doses, should not be expensive,
should have longer shelf life, freely available on the market, etc.
These criteria for an
anticancer drug are a tall order. Hardly there is any drug, synthetic or
natural, that meets with all these qualifications and so the choice is
dictated by the maximum compliance of the criteria and the philosophy of
the ‘lesser evil’. With the presence of a large number of different
types of cancer, each a kind of a syndrome, no single drug can be expected
to be effective against more than one, at the best a few of related
cancers. In the West there are very strict regulations governing drug
development enforced by the respective Governments. These regulations
impose heavy time and financial loads on drug development but have public
safety at heart. In fact, such rigour in drug development, marketing and
prescription should be implemented, more particularly, in the developing
countries.
Thus, several factors
made cancer drugs a multimillion dollar and multinational business, hardly
within the reach of the poor, even in the western world.
In the face of a largely depressing
scenario of the chemotherapeutic approach in developing safe, effective
and wide range synthetic or natural drugs, alternative therapies like
hormones, bone marrow transplants, immunotherapy, irradiation, etc., are
in practice. It has now become evident that a miracle cure is a myth.
Hence, the current focus is on prevention, early detection, and pre- and
post therapy management.
ANTI-NEOPLASTIC PLANTS IN ANCIENT INDIAN MEDICAL
LITERATURE
Cancer
must have been of at least of sporadic occurrence in ancient times but
since it was not known in the same manner as today, we cannot expect its
direct mention in classical Indian medical literature, although there are
many, unverified, claims of curing cancer using classical medication, by
several Ayurvedists. Certain of the symptoms described in classical
literature, like internal abscesses, malignant ulcers, internal tumours,
are indicative of the disease. On the basis of such an interpretation of
symptoms, some species of plants mentioned, for use against these
disorders, in Charaka Samhitha and Sushrutha Samhitha,
can be considered antineoplastic (Table 1). Although these species are
used in different other therapeutic contexts, their potential in relation
to cancer is hardly recognised and none of these finds a place in modern
cancer treatment.
TABLE 1
PLANTS
WITH ANTINEOPLASTIC ACTIVITY FROM CHARAKA SAMHITHA
AND SUSHRUTHA
SAMHITHA
(Data gathered by Dr
Mamatha Rao)
Internal abscesses:
Aegle
marmelos L. Rutaceae
Alangium
lamarckii Thw. Alangiaceae
Asparagus
racemosus Willd. Liliaceae
Barleria
prionitis L. Acanthaceae
Basella
rubra L. Basellaceae
Cleome
viscosa L. Capparaceae
Crataeva
religiosa Forst. Capparaceae
Gymnema
sylvestre Roxb.
Asclepiadaceae
Odina
wodier Roxb. Anacardiaceae
Plumbago
zeylanica L. Plumbaginaceae
Poa
cyanosuroides Retz. Poaceae
Pongamia
glabra Vent. Fabaceae
Pyrus
communis L. Rosaceae
Sesbania
grandiflora Pers. Fabaceae
Terminalia
chebula Retz. Combretaceae
Sinapis
glauca Roxb. Brassicaceae
|